Growth Hormone Research
Tesamorelin, sermorelin, and ipamorelin are often grouped together because all three can influence growth hormone signaling. But they work through different receptors, have different pharmacology, and have been studied for very different outcomes.
The Amino Report
PUBLISHED
UPDATED
9 min read
Tesamorelin, sermorelin, and ipamorelin are often discussed as though they belong in the same category.
At first glance, that makes sense.
All three can stimulate the body's own growth hormone signaling, and all three ultimately interact with the growth hormone–IGF-1 axis.
But biologically, they are not three versions of the same peptide.
Tesamorelin and sermorelin mimic growth hormone-releasing hormone and activate the GHRH receptor.
Ipamorelin takes a different route. It is a growth hormone secretagogue that acts through the ghrelin receptor, GHS-R1a.
That receptor difference changes the way these compounds signal—and helps explain why their research histories, pharmacology, and potential applications look different.
Understanding that distinction is the key to understanding all three.
Growth hormone secretion begins with a tightly regulated conversation between the hypothalamus and pituitary gland.
The hypothalamus produces growth hormone-releasing hormone, or GHRH.
GHRH travels to the pituitary gland and binds receptors on specialized cells called somatotrophs.
Those cells respond by releasing growth hormone.
Growth hormone then circulates throughout the body and also signals the liver and other tissues to produce insulin-like growth factor 1, better known as IGF-1.
Together, GH and IGF-1 participate in a wide range of biological processes involving:
body composition
protein metabolism
bone biology
tissue repair
energy metabolism
and cellular growth and maintenance
But GH secretion isn't constant.
The body normally releases growth hormone in pulses, with particularly strong pulses occurring during sleep.
That pulsatile biology is important because tesamorelin, sermorelin, and ipamorelin all stimulate endogenous GH release rather than simply supplying growth hormone itself.
The easiest way to understand these three compounds is to imagine two different doors leading into the growth hormone system.
The first door is the GHRH receptor.
Tesamorelin and sermorelin enter through this pathway.
The second is the growth hormone secretagogue receptor, also known as GHS-R1a or the ghrelin receptor.
Ipamorelin acts through this pathway.
Both receptor systems can ultimately stimulate pituitary GH secretion.
But they don't send identical signals.
That is why simply calling all three “GH peptides” misses one of the most interesting parts of their biology.
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone.
Structurally, it is based on the full GHRH sequence but includes a modification designed to improve stability.
Like natural GHRH, tesamorelin binds the GHRH receptor on pituitary somatotroph cells.
The result is increased endogenous growth hormone secretion and downstream increases in IGF-1.
What makes tesamorelin particularly notable is that it has progressed much further through human clinical research than most peptides discussed in this space.
Tesamorelin became an FDA-approved medicine in 2010.
Its approved indication is the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
That history gives researchers something relatively unusual in peptide science:
large controlled human trials demonstrating a measurable body-composition effect.
The tesamorelin clinical program generated significant interest because the changes weren't simply reflected on a scale.
Researchers specifically measured visceral adipose tissue—the metabolically active fat stored around internal organs.
Clinical trials demonstrated significant reductions in visceral abdominal fat among participants receiving tesamorelin.
That distinction matters.
Subcutaneous fat and visceral fat are biologically different tissues.
Visceral adipose tissue has particularly strong associations with metabolic health, making the ability to influence that compartment scientifically interesting.
Tesamorelin therefore became an important demonstration that stimulating the endogenous GH axis can produce measurable changes in human body composition.
Its approved use is specific to HIV-associated lipodystrophy and should not be confused with general weight-loss treatment.
But from a research perspective, the findings established something important:
GHRH-receptor stimulation can meaningfully influence body composition in humans.
Tesamorelin does not contain growth hormone.
Instead, it stimulates the pituitary gland to release the body's own GH.
That distinction separates GHRH analogs from administration of recombinant growth hormone.
The hypothalamic-pituitary system remains part of the signaling process.
Somatostatin—the body's natural inhibitory signal for GH secretion—also continues to influence the system.
This is one reason researchers are interested in GH secretagogues and GHRH analogs: they stimulate an existing endocrine pathway rather than simply replacing its final hormone.
Sermorelin approaches the same receptor from a somewhat different direction.
Human GHRH contains 44 amino acids.
Early research discovered that much of its GH-releasing activity resides within the first 29 amino acids.
Sermorelin is essentially that biologically active GHRH(1-29) fragment.
It binds the same GHRH receptor used by natural GHRH and tesamorelin.
Human studies have demonstrated that GHRH(1-29) can produce substantial increases in circulating growth hormone.
Researchers have also shown a dose-dependent GH response, providing direct evidence that the shorter peptide retains meaningful biological activity.
Sermorelin's 29-amino-acid structure makes it considerably shorter than native GHRH.
Yet it retains the portion of the molecule required to activate the GHRH receptor.
That made sermorelin valuable not only as a research compound but historically as a diagnostic tool for evaluating pituitary growth hormone reserve.
Researchers could administer GHRH(1-29) and measure the pituitary response.
A functioning pituitary should respond by releasing GH.
That history gives sermorelin a particularly clear biological identity:
it is a direct GHRH-receptor agonist designed to stimulate endogenous growth hormone release.
Because both compounds act through the GHRH receptor, it can be tempting to treat tesamorelin and sermorelin as interchangeable.
They aren't.
Their molecular structures differ.
Their pharmacokinetics differ.
And the amount of clinical research behind them differs substantially.
Tesamorelin was specifically engineered as a more stable GHRH analog and has undergone large controlled clinical trials.
Sermorelin is the shorter GHRH(1-29) fragment and has a long history in endocrine research examining pituitary GH release.
So while both use the same receptor pathway, the compounds themselves—and the evidence surrounding them—remain distinct.
Ipamorelin changes the comparison entirely.
It does not primarily act through the GHRH receptor.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that activates the GHS-R1a receptor, commonly known as the ghrelin receptor.
Ghrelin is a naturally occurring hormone involved in appetite, energy regulation, gastrointestinal function, and growth hormone secretion.
Activation of GHS-R1a can stimulate the pituitary gland to release GH.
So ipamorelin reaches the same endocrine system through a different receptor.
That is its defining difference.
Earlier growth hormone-releasing peptides could stimulate GH effectively, but some also increased other pituitary or adrenal hormones.
Ipamorelin was developed with greater selectivity in mind.
Early pharmacological research found that ipamorelin produced strong GH release while showing considerably less effect on ACTH and cortisol than several earlier GH secretagogues.
Researchers described it as the first selective growth hormone secretagogue.
That selectivity helped distinguish ipamorelin from earlier compounds such as GHRP-2 and GHRP-6.
Instead of broadly stimulating several endocrine pathways, ipamorelin appeared more focused on GH release.
That characteristic remains one of the primary reasons the compound continues to attract research interest.
The distinction between GHRH-receptor agonists and ghrelin-receptor agonists becomes especially interesting when researchers examine how the two systems interact.
GHRH and ghrelin signaling are not completely redundant.
They can stimulate growth hormone secretion through different cellular pathways.
GHRH-receptor activation primarily signals through pathways involving cyclic AMP.
GHS-R1a activation involves different intracellular signaling, including pathways that increase intracellular calcium.
Both can encourage somatotroph cells to release GH.
But they approach the cell through different molecular mechanisms.
This creates an important concept in GH research:
two compounds can influence the same hormone while acting through different receptors.
Because the two receptor systems are distinct, researchers have long been interested in interactions between GHRH signaling and growth hormone secretagogues.
Experimental research has shown that stimulation through both pathways can sometimes produce greater GH release than either signal alone.
Biologically, this makes sense.
One pathway can increase the readiness of pituitary somatotrophs while another provides a separate stimulatory signal.
This complementary signaling is one reason GHRH analogs and ghrelin-receptor agonists are frequently discussed together in growth-hormone research.
It also explains why understanding receptor biology matters more than simply comparing peptide names.
A rise in growth hormone is not necessarily the final outcome researchers care about.
Downstream effects matter.
GH signaling influences IGF-1 production and interacts with numerous tissues throughout the body.
Researchers studying the GH–IGF-1 axis have examined relationships with:
lean body mass
fat metabolism
bone turnover
exercise physiology
recovery
sleep
and age-related changes in body composition.
The relevance of each peptide therefore depends not simply on whether it increases GH, but on how that hormonal response translates into measurable biological outcomes.
This is where the evidence behind the three compounds begins to separate further.
Among these three peptides, tesamorelin has the most developed controlled human evidence for a specific body-composition effect.
Its clinical trials demonstrated reductions in visceral adipose tissue in its studied population.
That doesn't mean every effect associated with GH signaling has been proven for tesamorelin.
But it does mean researchers have demonstrated that manipulating the GHRH pathway with tesamorelin can produce measurable changes in a clinically relevant fat compartment.
That gives tesamorelin a unique position in this comparison.
Sermorelin's research story is somewhat different.
Its value comes from decades of work demonstrating that the active 1-29 fragment of GHRH can stimulate pituitary growth hormone secretion in humans.
Dose-response studies have shown clear GH responses following administration of GHRH(1-29).
That makes sermorelin useful for understanding the physiology of endogenous GH release.
Rather than having the same large body-composition trial history as tesamorelin, sermorelin's research foundation is more closely tied to pituitary responsiveness and GHRH physiology.
Ipamorelin's research appeal comes from another direction.
Its selective activation of the growth hormone secretagogue receptor gives researchers a way to stimulate GH without using the GHRH receptor at all.
That opens questions about:
receptor selectivity
GH pulse characteristics
interactions with GHRH signaling
and downstream GH/IGF-1 responses.
Human research with ipamorelin is less extensive than tesamorelin's clinical program, but its distinct receptor pathway makes it scientifically valuable.
It isn't simply a weaker or stronger version of sermorelin.
It is doing something different.
Growth hormone physiology is strongly pulsatile.
Large bursts of GH are separated by periods of relatively low circulating levels.
Sleep, exercise, nutrition, age, sex, and other hormones all influence those pulses.
Because tesamorelin, sermorelin, and ipamorelin stimulate endogenous secretion, researchers are interested not only in total GH exposure but also in how these compounds interact with the body's existing rhythm.
That differs fundamentally from simply maintaining continuously elevated GH concentrations.
Understanding those pulse dynamics may eventually help researchers determine why different secretagogues produce different downstream effects.
When comparing these compounds, the most useful first question isn't:
Which one is strongest?
It's:
Which receptor does it activate?
For tesamorelin:
GHRH receptor.
For sermorelin:
GHRH receptor.
For ipamorelin:
GHS-R1a—the ghrelin receptor.
From there, the differences become much easier to understand.
Tesamorelin is a modified GHRH analog with extensive clinical research and an approved therapeutic application.
Sermorelin is the active 1-29 fragment of GHRH with a long research history demonstrating endogenous GH release.
Ipamorelin is a selective growth hormone secretagogue that approaches the GH axis through a different receptor system.
All three ultimately influence growth hormone signaling.
But they don't take the same route.
Interest in the GH–IGF-1 axis isn't new.
What has changed is researchers' ability to influence the system at increasingly specific points.
Instead of simply administering growth hormone, peptide research allows investigators to ask more precise questions.
What happens when the GHRH receptor is stimulated?
What changes when the ghrelin receptor is activated instead?
How does peptide structure influence duration of signaling?
How important is pulsatile GH release?
Can different receptor pathways create different downstream effects even when both increase the same hormone?
Those questions turn what initially looks like a simple comparison into a much more interesting area of endocrine research.
Tesamorelin, sermorelin, and ipamorelin all interact with the growth hormone axis, but describing them as interchangeable “GH peptides” misses their most important differences.
Tesamorelin and sermorelin activate the GHRH receptor.
Ipamorelin activates the ghrelin receptor, GHS-R1a.
Tesamorelin brings substantial controlled human research demonstrating effects on visceral adipose tissue in its approved population.
Sermorelin provides decades of evidence showing that GHRH(1-29) can stimulate endogenous pituitary GH release.
Ipamorelin offers a distinct and comparatively selective route into GH secretion through growth hormone secretagogue receptor signaling.
The common destination is increased activity within the GH–IGF-1 axis.
The pathways used to get there are different.
And those differences—not simply the ability to increase growth hormone—are what make tesamorelin, sermorelin, and ipamorelin individually interesting areas of research.
SOURCES / REFERENCES
Primary sources include peer-reviewed human clinical trials, endocrine physiology studies, pharmacology research, and current U.S. regulatory information examining tesamorelin, sermorelin/GHRH(1-29), ipamorelin, growth hormone secretion, visceral adipose tissue, and GH–IGF-1 signaling. Evidence differs substantially among the three compounds: tesamorelin has controlled human body-composition trials and an FDA-approved indication, sermorelin has human research demonstrating GHRH-mediated pituitary GH release, and foundational ipamorelin selectivity research is primarily preclinical.
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370. DOI: 10.1056/NEJMoa072375.
Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311–322.
Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. DOI: 10.1001/jama.2014.8334.
U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) prescribing information. Revised March 2025.
Growth Hormone Research Society investigators. Low-dose growth hormone-releasing hormone tests: a dose-response study of GHRH(1-29)NH2. Clinical Endocrinology. 1994. PMID: 7921207.
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. DOI: 10.1530/eje.0.1390552.
Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. 2026;20(1):2–12. DOI: 10.1016/j.orcp.2026.01.002.
CONTINUE READING
Testing & Quality
A peptide labeled “99% pure” may sound nearly perfect. But that number answers a narrower analytical question than many people realize. Here’s what peptide purity can tell us—and what it cannot.
Testing & Quality
A Certificate of Analysis can look authoritative at a glance. But what information actually makes a COA useful—and what can a single document really establish about a peptide sample?
Peptide Library
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1, and glucagon receptors. Clinical research has reported substantial effects on body weight and metabolic measures, while important questions remain about long-term outcomes, tolerability, and emerging areas of study.
